Making innovationsreach patients
Reimbursement in the rare disease landscape is complex. IMAC specializes in the transformation of evidence into a value story that makes payers want to engage.
Reimbursement in the rare disease landscape is complex. IMAC specializes in the transformation of evidence into a value story that makes payers want to engage.
IMAC is a specialized market access consulting firm based on my decades of experience as an executive in the pharma industry and as a senior consultant in a large consulting company.
For well over 15 years, our inspired, dedicated, and specialist team has been the framework of our overall value. Our goal is to continue to demonstrate our relentless commitment—exemplifying our integrity, innovative solutions, and exceptional personalized support.
Since 2006, in this ever-evolving environment, we have collaborated with our clients bringing highly specialized technologies to targeted patient populations. IMAC has gained a vast knowledge of how to gain market access for your therapies and improve patient outcomes.
Louise Perraut
President and CEO
IMAC consists of highly experienced, senior consultants with decades of successful projects. Along with our extended network of experts, our team is uniquely positioned to provide innovative and strategic methods to ensure the success of your project.
The global reimbursement landscape is rapidly evolving, with more highly specialized therapies and treatments for rare diseases emerging every day. Our team has an unparalleled track record of success in navigating these complexities and securing access for innovative therapies.
Amid rising healthcare costs, strategic economic modeling is essential for successful reimbursement in today’s markets. Our highly experienced HEOR team brings decades of expertise in developing innovative economic models to support effective market access and reimbursement strategies.
Market access for rare diseases presents unique challenges: limited data, a knowledge gap among payers, higher pricing, and a lack of tailored evaluation frameworks. Partnering with our team, with deep expertise in rare disease market access strategies, helps overcome these barriers and ensures effective access for innovative treatments.
Real-world evidence (RWE) is increasingly crucial for informed decision-making by regulators, payers, and providers, shaping the evolving landscape of market access. Discover how our expertise in RWE generation can support your access strategy.
projects
countries
submission success
years of experience
We are a team of experts with decades of industry and consultancy experience that we put to use for you!
The size or our organization allows us to be adaptable, agile, and offer a customized service based on your organizational and project specific needs.
We are known for our innovative strategy and finding solutions for even the most challenging problems.
Your goals are our goals. We look to develop a long-lasting partnership. Our business runs on repeat customers who are highly satisfied with our support!
Our goal is to assist you to bring your therapy to patients in need. We believe in the incredible impact of your success in the lives of patients, their families, and the medical profession.
Eva has 30 years of research experience in academia, government, and the pharmaceutical industry and has been a consultant since 2006. Over this time period she has worked on over 200 projects.
Eva Tsakonas
Senior Consultant Market Access
Throughout his career, Patrick has held regional European and national roles in Market Access and Medical Affairs for companies such as Alnylam, Genzyme, Tesaro, Infinity, Amgen, and Ariad.
Patrick Barry
Senior Consultant Market Access Strategy Writer
With a background in neuroscience (PhD; University of Cambridge), Susan has over 13 years of experience developing compelling value communications to support HEOR and market access
Susan Bartko-Winters
Senior Consultant Market Access Strategy Writer
Christine specializes in data collection and analysis, with an academic background in mathematics and the humanities. She has worked for the academic and private sectors at national and international levels.
Christine Sehrbrock
Research and Data Analyst
Véronique has more than 20 years of experience in the pharmacoeconomic industry. With a master’s degree in economics, she is specialised in health economic evaluations.
Véronique Lauzon
Principal Health Economist
A skilled executive administrative professional with more than 20 years of experience in organizational and managerial roles.
Tamara Kradepohl
Executive Administrative Assistant
With more than 15 years of experience in medical communications, Nicole specializes in the development of persuasive, evidence-based content for varied audiences.
Nicole Tunstall
Vice President
As a pharmaceutical executive at the national and international level, Liette is a private payer specialist with extensive experience.
Liette Champagne
Senior Consultant, Pharmaceutical Industry and Private Payer Specialist
Kim is a practicing physician, who brings a unique mix of extensive medical writing and editing expertise, breadth of knowledge, and clinical experience to her projects.
Kim Turcotte
Senior Consultant, HTA and Medical Liaison
With almost 15 years of experience as an Information Specialist and research librarian in the health sciences, Dagmara has considerable experience.
Dagmara Chojecki
Information Specialist
Christelle is a Canadian drug regulatory and market access expert with a specialization in pharmacoeconomics and pharmacoepidemiology.
Christelle Iliza
Senior Consultant, Regulatory and Market Access Expert
Alexander is a medical communications specialist with experience in developing content for diverse audiences.
Alexander Callan
Senior Consultant, Medical Writer
Fill out the form below, and our dedicated team will be in touch to discuss tailored solutions for you.